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Abstract
Tryptophan, an essential amino acid through a series of enzymatic reactions gives 
rise to various metabolites, viz. serotonin and melatonin, that regulate distinct bio-
logical functions. We show here that tryptophan metabolism in the pineal gland fa-
vors bone mass accrual through production of melatonin, a pineal- derived 
neurohormone. Pineal gland- specific deletion of Tph1, the enzyme that catalyzes the 
first step in the melatonin biosynthesis lead to a decrease in melatonin levels and a 
low bone mass due to an isolated decrease in bone formation while bone resorption 
parameters remained unaffected. Skeletal analysis of the mice deficient in MT1 or 
MT2 melatonin receptors showed a low bone mass in MT2−/− mice while MT1−/− 
mice had a normal bone mass compared to the WT mice. This low bone mass in the 
MT2−/− mice was due to an isolated decrease in osteoblast numbers and bone for-
mation. In vitro assays of the osteoblast cultures derived from the MT1−/− and 
MT2−/− mice showed a cell intrinsic defect in the proliferation, differentiation and 
mineralization abilities of MT2−/− osteoblasts compared to WT counterparts, and 
the mutant cells did not respond to melatonin addition. Finally, we demonstrate that 
daily oral administration of melatonin can increase bone accrual during growth and 
can cure ovariectomy- induced structural and functional degeneration of bone by spe-
cifically increasing bone formation. By identifying pineal- derived melatonin as a 
regulator of bone mass through MT2 receptors, this study expands the role played by 
tryptophan derivatives in the regulation of bone mass and underscores its therapeutic 
relevance in postmenopausal osteoporosis.
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1 |  INTRODUCTION
Skeleton is one of the largest organ systems in the vertebrate 
body and performs multiple mechanical, hematopoietic and 
endocrine functions.1 Adult skeleton is continuously renewed 
through bone remodeling, a homeostatic process regulated by 
a fine balance in the actions of two cell types: osteoblasts that 
make new bone and osteoclasts that resorb old bone.2-5 Bone 
remodeling is regulated by paracrine, endocrine and neuroen-
docrine signals, and a dysregulation in any of these pathways 
affects skeletal physiology.6,7 Despite significant advances in 
our understanding of skeletal (patho- )physiology in the last 
20 years, only one anabolic therapy has reached the clinic that 
can effectively increase bone mass for at least up to 2 years 
in humans, ie, intermittent injections of parathyroid hormone 
(iPTH).8 The challenge therefore remains to identify additional 
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anabolic drug targets that can complement and/or are better 
than iPTH to prevent or cure osteoporosis in humans.
Melatonin is a bioamine generated in the pineal gland, but 
is also produced in several peripheral sites especially the gut.9-
12 Melatonin is synthesized from the essential amino acid tryp-
tophan following two pathways—the classical or an alternate 
pathway.9,10,12 The classical biosynthetic pathway is the pre-
dominant pathway through which melatonin is synthesized in 
the mammalian pineal gland, and it involves four consecutive 
steps.9,10,12 Tryptophan is first converted, through the action 
of tryptophan hydroxylase 1 (Tph1) into 5- hydroxytryptophan 
(Step 1), which is then converted into serotonin (Step 2) by 
the action of aromatic amino acid decarboxylase (AADC). 
Serotonin is next converted through the action of arylalkyl-
amine N- acetyltransferase (AANAT) into N-acetylserotonin 
(Step 3), which then serves as a substrate for the enzyme N- 
acetylserotonin O- methyltransferase (ASMT) that converts it 
to melatonin.9,10,12,13 An alternate pathway has been proposed 
recently that may play an important role in the production of 
melatonin in the peripheral tissues in which serotonin is first 
O- methylated and the resulting 5- methoxytryptamine is then 
N- acetylated to produce melatonin.12 Melatonin produced by 
the pineal gland is a neurohormone that is released into the 
circulation and regulates a variety of physiological processes 
by either acting through cell surface receptors, melatonin re-
ceptor 1A (MT1)/melatonin receptor 1B (MT2), or by acting 
directly as an antioxidant in the cells.14-17
Melatonin is known to regulate many functions including 
circadian rhythm, reproduction, temperature, immune system 
and the cardiovasculature, and therapeutic avenues are being 
explored for melatonin in the treatment of many diseases.18-23 
Melatonin has been shown to influence osteoblast functions 
in vitro and enhance bone regeneration in calvarial defect in 
explant assays.24,25 However, the cellular origin of melatonin 
synthesis and its potential as a regulator of bone mass ac-
crual in the in vivo context have not been thoroughly inves-
tigated.7,26 Given the biology surrounding melatonin and its 
receptors, and its clinical relevance as underscored above, it 
is of utmost importance to understand the cellular origin and 
the mechanisms through which melatonin affects bone mass.
Here we show that pineal- derived melatonin (PDM) pos-
itively regulates bone mass. Cell- specific gene deletion and 
oral feeding of melatonin in loss of function models show that 
melatonin regulation of bone mass accrual occurs through 
MT2 receptor. MT2 receptor expressed on the osteoblasts 
regulates, in a cell autonomous fashion, Cyclin expression 
to increase osteoblasts proliferation and function. We further 
show that oral melatonin treatment can cure gonadectomy- 
induced architectural deterioration and biomechanical 
properties of bones in rodents. These results reveal an un-
anticipated molecular link between pineal and bone through 
alterations in serum melatonin levels and identify novel ther-
apeutic avenues for treating postmenopausal osteoporosis.
2 |  METHODS
2.1 | Animals
We performed all procedures on mice conforming to the 
ethical regulations of National Institute of Immunology, 
Wellcome Trust Sanger Institute and the UK Home Office. To 
generate pineal- specific deletion (pineal−/−), Tph1flox/+ mice 
were crossed with Crx-Cre mice to generate pineal+/− mice, 
and their progeny were intercrossed to obtain Tph1pineal−/− 
mice. Generation of Tph1fl/fl, MT1−/−, MT2−/− and Crx-Cre 
mice was previously reported.27-30 We obtained C3H/HeJ and 
C57Bl6 mice from the inbred wild- type colonies maintained 
at the Wellcome Trust Sanger Institute and National Institute 
of Immunology research support facility.
2.2 | Curative regimen in mice
We subjected 6- weeks- old virgin C57Bl/6J female mice 
to either bilateral ovariectomy or sham operation. We next 
treated mice for 6 weeks starting 6 weeks after ovariectomy 
with melatonin (10 or 100 mg/kg body weight/d) or vehicle 
by oral gavage. At the end of experiments, animals were 
culled and the skeleton was fixed in 4% neutral buffered for-
malin or frozen for mechanical testing. Right tibia and lum-
bar vertebral column were collected in 70% alcohol and were 
processed for μCT or histomorphometric analysis.
2.3 | Histology and μCT of bones
Histological analyses were performed on vertebral column 
specimens collected from 3- month- old mice (unless otherwise 
stated) using undecalcified sections stained with von Kossa/
von Gieson or other reagents.30,31 Static and dynamic histomor-
phometric analyses were performed according to standard pro-
tocols using the Osteomeasure Analysis System (Osteometrics, 
Atlanta, GA, USA). μCT scanning of excised tibia was carried 
out as described before32 using a Skyscan 1172 μCT system 
with standard software provided by the manufacturer.
2.4 | Cell cultures
2.4.1 | Bromodeoxy uridine  
incorporation- based osteoblast 
proliferation assay
Primary calvarial osteoblasts from WT or mutant mice 
(MT1−/− or MT2−/−) were used for cell proliferation assays. 
Briefly, at 70%- 80% confluence cells were trypsinized, and 
5000 cells/well were seeded in 96- well plate in α- MEM sup-
plemented with 10% fetal bovine serum (FBS). After 24 hours, 
cells were left for another 24 hours in α- MEM supplemented 
with 0.5% FBS. Four hours before the end of 24 hours stimu-
lation period, the cells were pulsed with bromodeoxy uridine 
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(BrdU), and BrdU incorporation was measured using an 
ELISA kit (Roche, Indianapolis, IN, USA).
2.4.2 | Alkaline phosphatase activity assays
Primary calvarial osteoblasts from WT and or mutant mice 
(MT1−/− or MT2−/−) at 70%- 80% confluence were trypsinized 
and 5000 cells/well were seeded in 96- well plates. Cells from WT 
and mutant (MT1−/− or MT2−/−) mice were cultured for 48 hours 
in an osteoblast differentiation medium containing α- MEM sup-
plemented with 10% FBS, 10 mmol/L β- glycerophosphate, 
50 mg/mL of ascorbic acid and 1% penicillin/streptomycin. At the 
end of incubation period, total alkaline phosphatase (ALP) activ-
ity was measured by an alkaline phosphatase assay kit using p- 
nitrophenylphosphate (PNPP) as substrate, and color absorbance 
was read at 405 nm (SensoLyte® pNPP Alkaline Phosphatase 
Assay kit; AnaSpec, Inc., Fremont, CA, USA).
2.4.3 | Osteoblast mineralization assays
Primary osteoblasts from WT or mutant (MT1−/− or MT2−/−) 
mice were seeded in 12- well plates (25 000 cells/well) in oste-
oblast differentiation medium and cultured for 21 days with a 
medium change every 48 hours. At the end of the experiment, 
cells were washed with PBS and fixed with 4% paraformal-
dehyde for 15 minutes. Alizarin red- S was used for staining, 
visualizing mineralized nodules and quantification.
2.5 | Bioassays
Serum melatonin levels were quantified by ELISA (me-
latonin kit; IBL International, Hamburg, Germany). In the 
case of genetic ablation of Tph1 on C3H/HeJ or 129/SvJ, 
background blood was collected between 400 and 600 hours 
while in the case of pharmacological experiments with exog-
enous melatonin treatment blood was collected between 1400 
and 1600 hours. Blood was allowed to clot on ice before cen-
trifugation to collect the clear supernatant.
2.6 | Molecular studies
Total RNA was isolated from either primary calvarial os-
teoblasts or long bones flushed of bone marrow. Real- time 
PCR was performed on DNase I- treated total RNA converted 
to cDNA using appropriate primers and standard protocols. 
β- Actin amplification was used as an internal con-
trol. Quantitative RT- PCR primer sequences used in our 
study were as follows. MT1 (forward primer [F]: TGTGT 
ACCGCAACAAGAAGC; reverse primer [R]: GAGGCTG 
TGGCAAATGTAGC),  MT2 (F: CCTCTCAGTGCTCAGG 
AACC; R: CAGAGCCAATGACACTCAGG), Alp (F: CAGA 
GCCAATGACACTCAGG; R: TGGCTACATTGGTG 
TTGAGC), Runx2 (F: AGATGGGACTGTGGTTACCG; R: 
TGGTCAAGGTGAAACTCTTGC), Osx (F: CCTCTGCGG 
GACTCAACAAC; R: TGCCTGGACCTGGTGAGATG), 
Trap (F: AAACCCGTGAGGAAGAGAGC; R: GGACATT 
TTCCTCCTTCTTGG), RankL (F: GGAAGCGTACCTA 
CAGACTA; R: AGTACGTCGCATCTTGATCC), Opg 
(F: ACAGTTTGCCTGGGACCAAA; R: TCACAGAG 
GTCAATGTCTTGGA), Ccnd1 (F: GCGTACCCTGA 
CACCAATCTC; R: CTCCTCTTCGCACTTCTGCTC), 
Ccnd2 (F: GAGTGGGAACTGGTAGTGTTG; R: CGCAC 
AGAGCGATGAAGGT), Ccne1 (F: GTGGCTCCGACCT 
TTCAGTC; R: CACAGTCTTGTCAATCTTGGCA), Ccne2 
(F: ATGTCAAGACGCAGCCGTTTA; R: GCTGATTCCT 
CCAGACAGTACA), Ccnf (F: GTAGGCGATAGGTCA 
TACGGA; R: ACAATGGATCACTACCCCGTG) and 
β-Actin (F: GACCTCTATGCCAACACAGT; R: AGTAC 
TTGCGCTCAGGAGGA). OPG and Rankl expression 
was first normalized with β-Actin levels, and then, ratio 
OPG/Rankl was expressed as relative to the WT sam-
ple value. Genotypes of all the mice were determined by 
genomic DNA PCR. Genotyping primers used in our stud-
ies to genotype different mutant mice were as follows. 
MT1−/− mice (1A1: GAGTCCAAGTTGCTGGGCAG; 
1A2: GAAGTTTTCTCAGTGTCCCGC; 1A3: CCAGCTC 
ATTCCTCCACTCAT), MT2−/− mice (2B1: CCGCAGCC 
TCTTCTTAACAC; 2B2: CTGCCACTGAGGACAGAACA; 
2B3: GCCAGAGGCCACTTGTGTAG), Crx-Cre (Cre1: GA 
CGATGCAACGAGTGATGA; Cre2: AGCATTGCTGTCA 
CTTGGTC) and Tph1Floxed mice (F: GGATCCTAACC 
GAGTGTTCC; R: GCACACCACCAACTCTTTCC).
2.7 | Statistical analyses
Results are given as means±standard error. Statistical analy-
sis was performed by Student’s t test between two groups 
and one- way ANOVA followed by Newman- keuls post hoc 
test for more than two groups. Fold changes were calculated 
in gene expression compared to the vehicle- treated cells or 
WT samples. Results were considered significant at P<.05. 
In all the panels in Figures 1-3 and Figs S1-S3, following 
symbols have been used to indicate different levels of signifi-
cance: *P<.05, **P<.01 and ***P<.001 vs WT or control 
samples. In Figure 4, following symbols have been used to 
indicate different levels of significance: *P<.05, **P<.01 
and ***P<.001 as compared to OVX (vehicle); and !P<.05, 
@P<.01, #P<.001 as compared to sham (vehicle).
3 |  RESULTS
3.1 | Pineal- derived melatonin regulates 
bone mass
To understand whether pineal- derived melatonin regulates 
bone mass, we first generated a pineal- specific conditional 
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loss of function model of melatonin. Laboratory mouse 
strains differ significantly in their ability to produce mela-
tonin. We therefore carried out our analysis on two differ-
ent genetic backgrounds of mice: one that has normal levels 
of melatonin (C3H/HeJ, melatonin- proficient) and the other 
that has <1% of this level (129/SvJ, melatonin- deficient) in 
their serum. To achieve Tph1 ablation on C3H/HeJ genetic 
background, we backcrossed Tph1 floxed mice and Crx-Cre 
mice, a pineal- specific Cre recombinase, which were on 
pure 129/SvJ background for seven generations on a C3H/
HeJ background (Figure 1A). This backcrossing normalized 
the levels of melatonin in their serum to the one observed 
in pure C3H/HeJ mice, a melatonin- proficient strain (Fig. 
S1A). These melatonin- proficient Tph1 floxed and Crx-Cre 
mice were then intercrossed to generate Tph1pineal−/− mice. 
Tph1pineal−/− mice had a 65% reduction in Tph1 expression 
in pineal while Tph1 expression in skin, bone and gut was 
not affected compared to controls (Fig. S1B). Circulating 
melatonin levels were 60% lower in Tph1pineal−/− mice com-
pared to the control mice, demonstrating that Tph1- derived 
serotonin is a limiting factor in pineal melatonin biosynthesis 
(Figure 1B). As expected, Tph1pineal−/− or their wild- type 
littermates on 129/SvJ background had undetectable levels 
(below sensitivity [B.S.] of the assay used) of melatonin 
(Figure 1B).
Histological and histomorphometric analysis of skeleton 
at 12 weeks of age revealed that mice lacking Tph1 in the 
pineal on the melatonin- proficient C3H/HeJ background 
(Tph1pineal−/−) developed a low bone mass phenotype sec-
ondary to a decrease in osteoblast numbers and bone for-
mation rate, while bone resorption parameters were not 
affected compared to +/+ mice (Figure 1C and Fig. S1C,D). 
μCT analysis revealed that this low bone mass phenotype in 
Tph1pineal−/− mice was also present in the long bones as it 
was in the vertebra (Figure 1D). In contrast to the results ob-
tained on C3H/HeJ background, mice lacking Tph1 in pineal 
F I G U R E  1  Pineal- derived melatonin positively regulates bone mass. (A) Schematic representation of the breeding strategy to obtain 
Tph1pineal−/− on 129/SvJ (melatonin- deficient) and C3H/HeJ (melatonin- proficient) genetic backgrounds. (B) Recombination PCR for Tph1 in 
tissues and serum melatonin levels in different genotypes. (C) Histological analysis of vertebra. (D) μCT analysis of tibia in 12- wk- old +/+, +/+; 
Crx-Cre, Tph1fl/fl and Tph1pineal−/− mice on C3H/HeJ background. (E) Histological analysis of vertebra of 12- wk- old WT, +/+; Crx-Cre, Tph1fl/fl  
and Tph1pineal−/− mice on 129/SvJ background. (F) Serum melatonin, vertebral histomorphometry and serum osteocalcin levels in WT C57BL/6 
mice treated with 0, 10 or 100 mg/kg/d melatonin for 6 wk. n for each group is indicated within each panel. Values are mean±SEM. Following 
symbols have been used to indicate level of significance: *P<.05; **P<.01; ***P<.001 compared to WT or control samples. ns, not significant. 
See also Fig. S1
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on melatonin- deficient 129/SvJ background (Tph1pineal−/− 
mice) had a nonsignificant change in bone mass compared 
to +/+ mice (Figure 1E and Fig. S1E). These results on 
melatonin- deficient strain 129/SvJ (Figure 1E) underscore 
that Tph1- derived serotonin produced in the pineal gland on 
its own has no effect on bone mass acquisition, but when it is 
converted to melatonin in a melatonin- proficient strain such 
as C3H/HeJ (Figure 1C,D) and released in the circulation it 
positively regulates bone mass.
3.2 | Exogenous melatonin administration 
in the WT mice increases bone mass
The above loss of function experiments revealed that PDM 
is a positive regulator of bone mass. We reasoned that if this 
is the case, then exogenous administration of melatonin in 
a melatonin- deficient C57Bl/6 strain should increase bone 
mass. To address this question, we next fed 12- weeks- old 
female C57Bl/6 mice once daily with either vehicle or 
melatonin at doses 0, 10 or 100 mg/kg BW for 6 weeks 
(Figure 1F). Melatonin administration resulted in an eleva-
tion in the serum melatonin levels in a dose- dependent man-
ner (Figure 1F). Mice treated with 100 or even 10 mg/kg BW 
of melatonin had a higher bone mass than that of vehicle- 
treated (0) mice (Figure 1F and Fig. S1F). Consistent with 
the influence of PDM on osteoblast proliferation and bone 
formation, this increase in bone mass in the melatonin- treated 
mice was secondary to a major increase in bone formation 
parameters such as osteoblast numbers and serum osteocalcin 
levels (Figure 1F). In contrast to an effect on bone formation, 
bone resorption parameters were not affected (Figure 1F). 
Based on these data, it thus appears that PDM is a hormone 
promoting bone mass through an isolated effect on bone 
formation.
3.3 | The MT2 receptor mediates melatonin 
regulation of osteoblast functions
If PDM acts as a hormone to promote bone mass, it must act 
through a specific receptor(s) present on bone cells whose 
F I G U R E  2  Melatonin promotes bone mass through MT2. (A) Real- time PCR analysis of MT1 and MT2 expression in different tissues of 
the WT mice. (B) Real- time PCR analysis of MT1 and MT2 in calvarial preosteoblast, differentiated osteoblast and long bone of the WT mice. (C) 
Vertebral histomorphometry and serum levels of osteocalcin (Ocn) and Ctx in MT1+/+, MT1−/−, MT2+/+ and MT2−/− mice. (D) μCT analysis of 
tibia in MT1+/+, MT1−/−, MT2+/+ and MT2−/− mice. (E) Real- time PCR analysis of Cyclins and osteoblast marker genes in the tibia of MT1+/+, 
MT1−/−, MT2+/+ and MT2−/− mice. (F) Vertebral histomorphometry of vehicle or melatonin- treated +/+ and MT2−/− mice. n for each group 
is indicated within each panel. Values are mean±SEM. Following symbols have been used to indicate level of significance: *P<.05; **P<.01; 
***P<.001 compared to WT or control samples. ns, not significant. See also Fig. S2
BV/TV (%)
BFR (µm3/µm2/y)
Nb.Ob/T.Ar. (/mm)
OcS/BS
BV/TV (%)
BFR (µm3/µm2/y)
Nb.Ob/T.Ar. (/mm)
OcS/BS
(WT/ MT2–/– mice)
Melatonin (100 mg/kg/d) Analysis
6 wk
(A) (B)
(C) (D)
(E) (F)
   MT2 –/– (n=5) MT2 –/– (+Mel) (n=5)
BV/TV (%)         11         20.28±1.53          14.72±1.29*
Tb.N. (1/µm)          3.11 2.28±0.17*
Tb.Sp (µm)        24.24
19.69±2.01           20.37±1.
±0.23             3.15±0.15          3.10±0.20            
±0.53           24.32±1.32         23.35±0.85          29.71±1.32**
          +/+ (n=5)
12.2±0.7 9.5±0.6*     9.7±0.7*
277.2±24.0 193.1±9.8*   189.9±8.8**
145.8±6.8 109.3±9.3*         112.3±9.9*  
 16.1±0.7  16.3±0.4                  16.0±1.3
Ex
pr
es
si
on
 re
la
tiv
e 
to
 
W
T 
(F
ol
d)
Ccnd1     Ccnd2     Ccne1     Ccne2
0
0.5
1.0
1.5
   Runx2      Ocn         Osx      Col1a1
** ** ** ** *
** *
 Ocn (ng/mL)       36.8±4.8 23.0±2.7*
  Ctx (ng/mL)      18.2±2.7          18.2±1.5 17.9±2.4
              MT1                                            MT2
MT1 MT2
MT2
+/+ (n=5)
 –/– (n=5)
MT1
     +/+ (n=5)             –/– (n=5)          +/+ (n=5)         –/– (n=5)
Bo
ne
Ca
rti
la
ge
Br
ai
n
Gu
t
Ov
ar
y
He
ar
t
Li
ve
r
M
us
cl
e
Sp
le
en
Ex
pr
es
si
on
 re
la
tiv
e 
to
 
bo
ne
 (F
ol
d)
0
0.5
1.0
1.5
0
1.0
2.0
3.0
4.0
5.0
Pr
e-O
sb Os
b
Bo
ne
Ex
pr
es
si
on
 re
la
tiv
e 
to
 
pr
e-
O
sb
 (F
ol
d)
MT1
MT2
11.06±0.29 11.33±1.15 11.14±0.31 8.83±0.71*
    18.4±1.8 
  16.1±1.5   16.1±0.1 16.1±1.216.5±1.0
143.7±22.9*234.4±9.7 233.2±11.0             210.0±4.1     
261.3±24.7       264.2±17.0              256.3±9.9     177.5±15.3**
     +/+ (n=5)             –/– (n=5)          +/+ (n=5)         –/– (n=5)
Each sample n=3  
+/+ (n=5)
 –/– (n=5)
1 mm
*
MT1
MT2
Each sample n=3  
35.4±4.1 37.2±3.8
6 of 12 |   SHARAN et Al.
inactivation should lead to a low bone mass phenotype. 
Among the two specific cell surface melatonin receptors, 
MT1 and MT2 both are expressed in bone (Figure 2A). MT2 
receptor, however, is more restricted to the bones among the 
tissues analyzed, and its expression in bone was fourfold 
higher than that of MT1 receptors (Figure 2B). To under-
stand which of these receptors is downstream to PDM, we 
performed histological and μCT analysis of the WT and mice 
lacking MT1 or MT2 on a melatonin- proficient C3H/HeJ ge-
netic background. Histomorphometric analysis of vertebra of 
MT1−/− mice at 12 weeks of age failed to detect any abnor-
malities in osteoblast number, bone formation, bone resorp-
tion and bone mass compared to +/+ mice (Figure 2C and 
Fig. S2A). In contrast, mice lacking MT2 displayed a low 
bone mass phenotype compared to +/+ mice (Figure 2C). 
This low bone mass was due to a decreased osteoblast num-
ber and bone formation rate (Figure 2C). In contrast to the 
effect of MT2 loss of function on osteoblasts, and like the 
effect of PDM melatonin, bone resorption parameters were 
not affected in these mutant mice compared to +/+ mice 
(Figure 2C and Fig. S2B). μCT analysis of long bones 
showed that MT2−/− mice had profoundly reduced bone 
volume, trabecular number and increased trabecular separa-
tion accounting for their low bone mass phenotype, while 
MT1−/− mice were similar to +/+ mice in all the param-
eters (Figure 2D). Gene expression analysis revealed a major 
decrease in Cyclin expression in MT2−/− mice while it re-
mained unchanged in MT1−/− mice indicating a decreased 
osteoblast proliferation (Figure 2E). Accordingly, mark-
ers of osteoblasts differentiation were reduced in MT2−/− 
mice bone (Figure 2E). Besides, treatment of 12- week- old 
MT2−/− mice with melatonin at 100 mg/Kg BW/d failed 
to increase the bone mass (Figure 2F and Fig. S2C). These 
results indicate that melatonin uses one predominant recep-
tor, MT2, to affect bone mass at both axial and appendicular 
skeleton.
F I G U R E  3  Melatonin directly regulates osteoblast functions through MT2 receptor. (A) BrdU incorporation assay in melatonin- treated 
WT calvarial osteoblasts. (B) BrdU incorporation assay in MT1+/+, MT1−/−, MT2+/+ and MT2−/− osteoblasts treated with vehicle or 
melatonin. (C, D) Real- time PCR analysis of Cyclins in vehicle or melatonin- treated WT osteoblasts (C) and in MT1+/+, MT1−/−, MT2+/+ and 
MT2−/− osteoblast cells (D). (E) Alkaline phosphatase activity in WT osteoblasts treated with melatonin at different concentrations. (F) Alkaline 
phosphatase activity in MT1+/+, MT1−/−, MT2+/+ and MT2−/− osteoblasts treated with vehicle or melatonin. (G) Real- time PCR analysis of 
osteoblast marker genes and (H) OPG/RankL expression ratio in melatonin- treated WT osteoblasts. (I) Alizarin red staining and quantification 
in WT cells treated with melatonin for 21 d. (J, K) Alizarin red staining (J) and quantification (K) in the calvarial osteoblast cells from MT1+/+, 
MT1−/−, MT2+/+ and MT2−/− mice differentiated toward mineralizing osteoblasts. n for each group is indicated within each panel. Values are 
mean±SEM. Following symbols have been used to indicate level of significance: *P<.05; **P<.01; ***P<.001 compared to WT or control 
samples. ns, not significant. See also Fig. S3
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3.4 | Melatonin directly regulates osteoblast  
functions
Melatonin regulation of bone formation through MT2 recep-
tors raises the question whether melatonin directly acts on 
bone cells to regulate their functions or does so indirectly. 
To address this issue, we used primary calvarial osteoblast 
cultures to identify whether melatonin regulates osteoblast 
functions directly.
First, we analyzed the effect of melatonin on primary osteo-
blasts proliferation, differentiation and mineralization. To de-
termine if osteoblast proliferation was affected by melatonin, 
we measured the number of cells actively synthesizing DNA by 
BrdU incorporation in vitro. Melatonin significantly increased 
the proliferation of preosteoblasts in a dose- dependent manner 
compared to the vehicle- treated cells (Figure 3A) with a max-
imum increase of approximately 1.5- fold at 100 nmol/L con-
centration. Analysis of osteoblasts proliferation from MT1 and 
MT2 knockout cells revealed a 50% decrease in proliferation 
in MT2- deficient osteoblasts while MT1- deficient osteoblasts 
proliferated similar to their WT counterparts (Figure 3B and 
Fig. S1A). Importantly, melatonin failed to increase prolifer-
ation in MT2- deficient osteoblasts, but it raised their prolif-
eration to the same extent as the WT cells in MT1−/− cells 
(Figure 3B). Molecularly, this increase in proliferation was 
partly due to the rapid increase in the expression of Cyclins 
observed in these cells upon melatonin treatment that was ab-
sent in the MT2−/− osteoblasts (Figure 3C,D).
We next determined whether melatonin regulates differ-
entiation potential of osteoblasts using two different assays: 
alkaline phosphatase activity assays and marker gene ex-
pression analysis. Melatonin was very effective in increasing 
osteoblast differentiation at all the concentrations tested and 
ALP activity increased by 2.5- fold at 100 nmol/L concentra-
tion (Figure 3E). Melatonin failed to increase ALP activity 
observed in MT2−/− osteoblasts (Figure 3F). At the gene 
expression levels, melatonin increased markers of osteoblast 
differentiation while it did not affect OPG/RankL ratio, an 
increase absent in MT2- deficient osteoblasts (Figure 3G,H & 
data not shown).
F I G U R E  4  Daily melatonin treatment cures ovariectomy- induced osteoporosis. (A) Schematic representation of the experimental protocol 
used and representative images of von Kossa stained vertebral sections of sham/OVX mice treated with vehicle or melatonin at 10 or 100 mg/kg/d 
dose. (B) Vertebral histomorphometric analysis in sham and OVX mice treated with vehicle or melatonin at 10 or 100 mg/kg/d dose. (C, D) 3D 
μCT images of proximal tibia (C) and its microarchitectural parameters (D) in sham/OVX mice treated with vehicle or melatonin. (E- G) Serum 
melatonin (E), osteocalcin (F) and Ctx levels (G) in sham/OVX mice treated with vehicle or melatonin. (H, I) Femur stiffness (H) and femur 
maximum force analysis (I) by three- point bending test in sham/OVX mice treated with vehicle or melatonin. Values are mean±SEM. n for each 
group is indicated within each panel. Results were considered significant at P<.05. In all the panels, following symbols have been used to indicate 
different levels of significance *P<.05, **P<.01 and ***P<.001 as compared to OVX (vehicle) and !P<.05, @P<.01, #P<.001 as compared to 
sham (Veh)
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Lastly, we looked at the effect of melatonin on the osteo-
blasts function by analyzing changes in mineralization in the 
presence and absence of melatonin. Quantitative analysis of 
this assay showed that melatonin increased the calvarial osteo-
blast mineralization in WT and MT1−/− by 30% (Figure 3I) at 
100 nmol/L. While basal level of mineralization was decreased 
in MT2−/− calvarial osteoblasts, melatonin failed to increase it 
(Figure 3J,K). Further, bone marrow stromal cells from MT2−/− 
mice had a decrease (60%) in mineralization as compared to WT 
and MT1−/− mice (Figure 3, Fig. S3A,B) indicating a decrease 
in the number of osteoprogenitor cells in the bone marrow.
Taken together, these results demonstrate that direct ac-
tion of melatonin on osteoblasts accounts, at least in part, to 
the overall regulation of bone mass through melatonin MT2 
pathway.
3.5 | Melatonin treatment cures mice from 
ovariectomy- induced bone loss
To assess the biological importance of the melatonin regula-
tion of bone formation, we tested the therapeutic relevance of 
melatonin- dependent increase in bone formation, through the 
use of ovariectomized (OVX) rodents that present, as post-
menopausal women do, a decrease in bone mass.
We first tested whether melatonin treatment when given 
significantly late after ovariectomy can cure ovariectomy- 
induced bone loss. For this purpose, 6- week- old mice were 
OVX or sham- operated and were left untreated for 6 weeks 
before being treated with vehicle or melatonin at 10 or 100 mg/
kg/d for another 6 weeks (Figure 4A). Osteoclast surface and 
serum CTX levels, a marker of bone resorption, were higher 
in OVX mice, regardless of their treatment, than in sham- 
operated animals, and as a result, vehicle- treated OVX mice 
developed a low bone mass (osteopenia; Figure 4A,B). In 
contrast, OVX mice treated with 10 or 100 mg/kg/d of mela-
tonin had a higher bone mass than that of vehicle- treated OVX 
mice, and at 100 mg/kg BW/d the bone mass of OVX mice 
was similar to that of sham- operated mice (Figure 4A,B). 
Consistent with the influence of melatonin on osteoblast pro-
liferation and bone formation, this increase in bone mass in 
the melatonin- treated OVX mice was secondary to a major 
increase in bone formation parameters such as osteoblast 
numbers and bone formation rate (Figure 4B). μCT analysis 
of long bones showed that melatonin rescued low bone mass 
in the long bones as it did in the vertebrae (Figure 4C,D). We 
verified that serum melatonin levels and markers of osteo-
blasts (OCN) and osteoclasts function (Ctx) in serum were 
increased in melatonin- treated OVX mice compared to sham 
(Figure 4E- G). There was no change in bone length or width 
in any of the groups treated with melatonin (data not shown). 
These results establish that melatonin can rescue, through 
a bone anabolic mechanism, OVX- induced osteoporosis in 
mice when given late after ovariectomy.
3.6 | Melatonin treatment restores 
ovariectomy- induced loss in bone quality
Ovariectomy- induced deterioration in the bone architecture 
leads to a decrease in the biomechanical properties of bone 
or the bone quality.33 To evaluate the potential value of in-
creasing melatonin levels in the treatment of low bone mass 
diseases, it is essential to assess whether melatonin treat-
ment restores the deterioration in bone quality observed after 
ovariectomy.
To address this question, we next measured the femur 
stiffness and femur ultimate load, two surrogates of bone 
quality, upon melatonin treatment in the curative regimen. 
To measure bone quality, femur samples from untreated and 
melatonin- treated OVX mice were subjected to a three- point 
bending test and a compression analysis, to determine stiff-
ness and maximal load (Figure 4H,I). Both parameters that 
were decreased after ovariectomy were restored, completely, 
in OVX mice treated with melatonin at 100 mg/kg/d treat-
ment to the values seen in sham- operated mice (Figure 4H,I). 
Thus, daily oral administration of melatonin could revert 
the bone loss, architectural deterioration and lost bone qual-
ity caused by a long- term gonadal failure in mice through a 
major increase in bone formation.
4 |  DISCUSSION
This study uncovers an unanticipated molecular mechanism 
accounting for the melatonin regulation of bone mass. Our 
studies with a mouse genetic model of Tph1 deficiency in the 
pineal gland using Crx-Cre driver dissect the importance of 
pineal- derived melatonin vs extra- pineal synthesized mela-
tonin in the regulation of bone mass. We further showed that 
one mechanism through which PDM regulates bone mass is 
through MT2- receptor dependent regulation of osteoblast 
proliferation and function. These studies identify another 
tryptophan- derived central molecule in the endocrine regula-
tion of bone mass (Figure 5). Moreover, given the fact that 
melatonin and ramelteon, an MT1/MT2 receptor agonist34 
are being used to treat sleep disorders in humans,35 this study 
provides mechanistic basis on which future therapeutic regi-
mens could be built upon to treat bone diseases characterized 
by a relative or absolute decrease in bone formation.
4.1 | Melatonin regulation of bone mass 
through MT2 receptor
In the present study, through pineal- specific gene deletion 
and pharmacological experiments, we have demonstrated an 
important role of melatonin in the regulation of bone mass. In 
vivo pharmacological manipulations in melatonin- deficient 
mice and ablation of melatonin synthesis in the pineal gland 
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showed that melatonin profoundly affects bone mass second-
ary to an isolated effect on the osteoblast numbers in the bone 
in vivo. Investigation into the means through which mela-
tonin affects osteoblast functions revealed that both MT1 and 
MT2 receptors are expressed on osteoblasts. According to 
gene deletion and in vitro experiments, MT2 is the receptor 
responsible for the effect of melatonin on osteoblasts, while 
inactivation of MT1 does not affect bone mass. However, 
both in the pineal- derived melatonin- deficient mice and in the 
MT2 null mice we did not observe any significant change in 
the osteoclasts parameters tested. This cellular phenotype in 
vivo in the bone is different than the earlier studies that have 
shown that melatonin affects osteoclasts function in vitro.36 
The lack of effect in vivo could therefore point toward other 
indirect mechanisms at play through melatonin that offset 
the direct effect of melatonin on osteoclasts. However, we 
must point out that we have only measured few parameters of 
osteoclast functions and it is possible that under certain con-
ditions and in other genetic backgrounds melatonin may af-
fect osteoclast biology in vivo. Together, these studies reveal 
an important role of melatonin signaling in the regulation of 
bone mass through MT2 receptors in vivo.
4.2 | Melatonin regulation of 
osteoblast functions
Melatonin affects multiple aspects of osteoblast biology 
to regulate bone mass. In vitro studies show that mela-
tonin increases osteoblasts proliferation, differentiation and 
mineralization. These results are consistent with earlier stud-
ies that have shown a positive effect of melatonin signaling 
on the osteoblasts.24,25,36-39 Melatonin receptors have been 
shown to be expressed on the osteoblasts, and previous stud-
ies have shown that melatonin positively regulates osteoblast 
functions.24,25,36,38,39 Our studies have now further extended 
these findings by identifying a specific receptor MT2 through 
which melatonin impinges on these osteoblast functions. One 
limitation of the present study is that we have used mice that 
lack MT2 in all the cells and future studies would be needed 
to specifically inactivate MT2 receptor in osteoblasts to un-
derstand the contribution of osteoblast vs other organ expres-
sion of MT2 in the regulation of bone mass. However, the 
fact that MT2- deficient osteoblasts show similar molecular 
and functional defects and are refractive to melatonin addi-
tion in vitro demonstrated that MT2 signaling in osteoblasts 
could play an important role in osteoblasts physiology in 
vivo. Another potential limitation of our results when meas-
uring molecular basis of functional osteoblast defects is that 
we have only measured the steady- state mRNA levels of the 
molecular markers of osteoblast functions, receptors and 
pineal Tph1 expression and have not measured the protein 
levels. It is therefore possible that the mRNA changes in the 
reported genes may not translate to a decrease in the protein 
levels. However, our results using BrdU incorporation for the 
proliferation, alkaline phosphatase activity assays for differ-
entiation, alizarin red staining that stains mineralized nodules 
and pineal melatonin synthesis support the conclusion that 
reported changes in genes expression underlie the reported 
defects in the cellular functions. Moreover, these results are 
consistent with earlier studies that have shown that Tph1 is 
the first step in the melatonin synthesis and that MT2 is the 
primary receptor responsible for the melatonin effect on the 
osteoblasts in vitro.12,38
Our results, supported through systematic loss and gain of 
function studies with three different strains of mice (C57Bl6, 
C3H/HeJ and Sv129), point toward melatonin affecting bone 
mass through an effect on bone formation rather than resorp-
tion in the female mice in vivo. Melatonin has been shown to 
have different effects on the skeleton depending on the sex 
of the mice and the dose of melatonin utilized. In contrast to 
our studies on the female skeleton, it has been reported that in 
the male mice the mechanism used by melatonin to increase 
bone mass during growth is through the inhibition of bone 
resorption.40 It is important to note here that gonadal failure- 
induced osteoporosis is a problem predominantly faced by 
females after menopause and is rare to observe gonadal fail-
ure in males. These results also underscore that evolutionarily 
the systems have evolved differently in males and females to 
respond to melatonin during growth or aging. In the ovariec-
tomized mice, a low dose of melatonin had no effect on the 
ovariectomy- induced bone loss in the rats.41 This is consis-
tent with our findings wherein we did not see a statistically 
F I G U R E  5  Model of melatonin regulation of bone mass. 
Diagrammatic representation of the proposed pathway through which 
pineal- derived melatonin regulates bone mass. Tryptophan regulates 
through a series of reactions the synthesis of pineal- derived melatonin 
(PDM) in a Tph1- dependent manner. PDM then enters the blood 
stream and acts on the osteoblasts through MT2 receptors to positively 
regulate bone mass. Trp, tryptophan; Tph1, tryptophan hydroxylase 
1; 5- HTP, 5- hydroxytryptophan; AADC, aromatic amino acid 
decarboxylase; AANAT, arylalkylamine N- acetyltransferase; ASMT, 
N- acetylserotonin O- methyltransferase
Tph1Trp
5-HTP
Melatonin
Osb
Bone mass
BonePineal gland
MT2
Brain
Bone formation
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significant increase in bone mass in the ovariectomized mice 
treated with 10 mg/kg BW/d of melatonin and only saw a res-
cue of bone mass in the ovariectomy experiment when mice 
were treated with a higher dose of melatonin at 100 mg/kg 
BW/d (Figure 4).
4.3 | Multiple facets of tryptophan 
derivatives in the regulation of bone mass
The identification of pineal- derived melatonin as a regulator 
of bone mass in the present study adds another molecule to 
the growing list of tryptophan derivatives that regulate bone 
mass. Tryptophan is an essential amino acid that is converted 
to a variety of metabolites in different cell types to perform 
distinct biological functions.12,42-44 Earlier studies have 
shown that in the gut, tryptophan is converted to serotonin 
(gut- derived serotonin, GDS), by the rate- limiting enzyme 
Tph1, that is a hormone and a potent inhibitor of bone forma-
tion in mice and humans.45,46 In contrast to the GDS, brain 
derived serotonin (BDS) synthesized by serotonin neurons of 
the hind brain acts as a neurotransmitter and is a positive reg-
ulator of bone mass.31 Like the BDS, PDM whose precursor 
is tryptophan positively regulates bone mass. This preced-
ing statement, however, needs further clarification. Although 
our results using Tph1pineal−/−, MT2 receptor- deficient 
and pharmacological models using melatonin- deficient and 
melatonin- proficient strains all point toward PDM playing an 
important role in the biology of bone, the results with the 
Tph1pineal−/− mice need to be viewed in the following con-
text. Mice that are deficient in Tph1 in the pineal gland will 
be hypothetically defective in the following molecules which 
are known to get diffused or transported outside the cells, 
viz. 5- hydroxytryptophan, serotonin, N- acetyl serotonin and 
melatonin. All of these molecules at pharmacological doses 
have the potential to affect bone mass. However, melatonin 
treatment studies with melatonin- deficient C57BL/6 and 
melatonin- proficient MT2 null mice on C3H/HeJ background 
support our conclusion that melatonin is the principle product 
that is involved in the regulation of bone mass in these mouse 
models. Together, these mouse and human genetic studies 
have identified an important role played by tryptophan and 
its metabolites in the regulation of bone mass and have il-
lustrated that the same molecule serotonin operates through 
multiple organs, viz. pineal gland, gut and brain to regulate 
bone mass.
4.4 | Therapeutic implications of  
pineal- bone axis
The identification that PDM regulates bone mass through 
a specific receptor has important therapeutic implication 
for the following reasons. First, melatonin is a natural mol-
ecule, and its absence or abundance does not lead to any 
pathological state as mice that have very low/negligible or 
high melatonin levels are healthy and have minor differences 
in the physiological functions.47 Second, melatonin has been 
used successfully to cure sleep disorder at much higher doses 
than the one tested in the present study.48,49 Third, the fact 
that pineal gland gets calcified in adult humans underscores 
that enhancement in melatonin levels/its receptor activity in 
adults might not lead to adverse consequences on physiologi-
cal functions.50
5 |  CONCLUSIONS
Our analysis of mouse genetic and pharmacological mod-
els with and without melatonin treatment has identified a 
novel endocrine axis operational through the pineal gland in 
the regulation of bone mass. Results show that ablation of 
melatonin synthesis in the pineal gland or its MT2 recep-
tors in the bone leads to a low bone mass phenotype due 
to an isolated defect in the bone formation. Inactivation of 
the MT2 and not the MT1 receptors leads to a cell intrinsic 
defect in the osteoblasts ability to proliferate, differentiate 
and deposit new bone matrix. Importantly, gain of function 
experiments revealed that oral administration of melatonin 
leads to an increase in bone mass in the young WT mice 
and is able to reverse completely the architectural deterio-
ration and functional defects in bone in a mouse model of 
menopause- induced osteoporosis. These results underscore 
the power of an integrative approach to bone physiology 
and raise several novel questions. For instance, and from a 
biological point of view we do not know yet whether PDM 
affects other endocrine axes that in turn regulate bone mass. 
From a therapeutic point of view, the fact that melatonin res-
cues ovariectomy- induced osteoporosis in mice holds great 
promise given that melatonin has been used successfully to 
cure sleep disorders. Further experiments will be needed to 
determine whether pharmacologically activating MT2 using 
more selective receptor agonist(s) or oral melatonin adminis-
tration is a valid approach in the treatment of low bone mass 
diseases.
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